Crinetics Pharmaceuticals explores rare endocrine treatments, PALSONIFY development, biotechnology operations, and healthcare innovation within the Nasdaq Composite market environment.

In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...

(Beyond Pesticides, February 5, 2024) Public Comment Period Ends February 26, 2024. The U.S. Environmental Protection Agency (EPA) never completed protocol for testing pesticides that disrupt the ...

Many BYU students strive to take care of their health, but their efforts may be thwarted by an item as unassuming as a kitchen skillet. Utahn Cara Clark had two young children when her doctor gave her ...

A new review was published in Volume 18 of Aging on June 11, 2026, titled "Age-related dysfunctions of the neuroendocrine ...

Treatment Algorithms for Hormone Receptor–Positive Advanced Breast Cancer: Going Forward in Endocrine Therapy—Overcoming Resistance and Introducing New Agents ER+ breast cancers can exhibit de novo or ...

Preeclampsia is a hypertensive disorder of pregnancy arising from aberrant placental development and dysregulated endocrine communication between maternal, placental and fetal compartments. Under ...